Molecular benchmarks of a SARS-CoV-2 epidemic.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
15 06 2021
15 06 2021
Historique:
received:
04
08
2020
accepted:
21
05
2021
entrez:
16
6
2021
pubmed:
17
6
2021
medline:
13
7
2021
Statut:
epublish
Résumé
A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control can be assessed with molecular information during a well characterized epidemic in Iceland. We demonstrate how the viral concentration decreased in those newly diagnosed as the epidemic transitioned from exponential growth phase to containment phase. The viral concentration in the cases identified in population screening decreased faster than in those symptomatic and considered at high risk and that were targeted by the healthcare system. The viral concentration persists in recovering individuals as we found that half of the cases are still positive after two weeks. We demonstrate that accumulation of mutations in SARS-CoV-2 genome can be exploited to track the rate of new viral generations throughout the different phases of the epidemic, where the accumulation of mutations decreases as the transmission rate decreases in the containment phase. Overall, the molecular signatures of SARS-CoV-2 infections contain valuable epidemiological information that can be used to assess the effectiveness of containment measures.
Identifiants
pubmed: 34131116
doi: 10.1038/s41467-021-23883-6
pii: 10.1038/s41467-021-23883-6
pmc: PMC8206085
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3633Références
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Commun. 2020 Sep 1;11(1):4376
pubmed: 32873808
Int J Infect Dis. 2006 Jan;10(1):32-7
pubmed: 16023880
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Cell. 2020 May 28;181(5):990-996.e5
pubmed: 32386545
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
N Engl J Med. 2020 Nov 26;383(22):2184-2185
pubmed: 33147384
Mol Biol Evol. 2016 Apr;33(4):863-9
pubmed: 26882983
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Front Microbiol. 2017 Feb 02;8:108
pubmed: 28210243
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9241-9243
pubmed: 32269081
Nat Genet. 2017 Nov;49(11):1654-1660
pubmed: 28945251
J Virol. 2018 Jun 29;92(14):
pubmed: 29720522
Cell. 2020 May 28;181(5):997-1003.e9
pubmed: 32359424